MYL(SH:600993)2023-04-28 16:00Financial Performance - The company's operating revenue for Q1 2023 was ¥832,651,815.62, representing a year-on-year decrease of 12.27%[18]. - Net profit attributable to shareholders of the listed company increased by 36.39% year-on-year to ¥187,605,800.02, primarily due to investment income from the disposal of Dafo Pharmaceutical equity[2][18]. - The net profit after deducting non-recurring gains and losses was ¥142,326,443.10, reflecting a year-on-year increase of 3.50%[18]. - The basic earnings per share for Q1 2023 was ¥0.44, an increase of 37.50% compared to the same period last year[18]. - Net profit for Q1 2023 was RMB 195,048,378.73, representing a 34.5% increase from RMB 144,892,354.29 in Q1 2022[40]. - Operating profit for Q1 2023 was RMB 233,355,004.23, up 41.0% from RMB 165,688,692.82 in Q1 2022[40]. - The company’s total profit for Q1 2023 was RMB 232,923,106.20, an increase of 41.0% from RMB 165,135,861.13 in Q1 2022[40]. - The company reported a significant increase in accounts receivable by 42.78%, attributed to expanded sales in the pharmaceutical industrial sector[21]. Assets and Liabilities - Total assets as of March 31, 2023, were ¥5,044,016,902.64, a slight decrease of 0.27% from the end of the previous year[18]. - The total liabilities amount to 1,286,650,695.43 RMB, a decrease from 1,438,754,527.44 RMB in the previous period[28]. - Total equity attributable to shareholders of the parent company is 3,644,300,900.76 RMB, up from 3,496,240,837.10 RMB[28]. - The company reported a decrease in current liabilities from 858,138,745.38 RMB to 666,079,458.40 RMB[28]. - The company’s total liabilities increased to 1,519,270,644.56 RMB in Q1 2023 from 958,855,138.01 RMB in Q1 2022, reflecting a 58% rise[38]. - The total assets of the company reached RMB 5,296,989,950.08 as of March 31, 2023, compared to RMB 4,542,658,025.63 as of December 31, 2022, reflecting an increase of about 16.6%[66]. - Total liabilities amounted to ¥1,191,905,765.50, with current liabilities at ¥495,641,765.22[58]. Cash Flow - The company's cash flow from operating activities showed a net outflow of ¥90,728,201.78, which is not applicable for year-on-year comparison[18]. - In Q1 2023, the company reported a net cash flow from operating activities of -90,728,201.78 RMB, an improvement from -137,319,701.64 RMB in Q1 2022, indicating a 34% reduction in cash outflow[34]. - The company reported a net cash increase of RMB 254,314,841.27 in Q1 2023, contrasting with a decrease of RMB 368,389,763.80 in Q1 2022[45]. - The net cash flow from operating activities for Q1 2023 was RMB 582,847,645.15, a significant increase compared to RMB 92,626,086.99 in Q1 2022, reflecting a year-over-year growth of over 528%[72]. - Cash inflow from investment activities totaled RMB 1,054,520,094.84 in Q1 2023, compared to RMB 487,781,372.45 in Q1 2022, indicating a growth of approximately 116.5%[72]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 34,973[23]. - The largest shareholder, China Baoan Group Co., Ltd., holds 126,163,313 shares, accounting for 29.27% of the total shares[23]. - The total number of shares held by the top ten shareholders includes significant stakes from various investment funds and individuals, indicating a diverse shareholder base[25]. Research and Development - Research and development expenses for Q1 2023 were RMB 14,861,949.84, slightly down from RMB 15,315,072.34 in Q1 2022[40]. - Research and development expenses for Q1 2023 were ¥17,029,168.21, slightly down from ¥17,671,619.69 in Q1 2022[59]. Investment Activities - The company disposed of non-current assets, resulting in a gain of ¥50,613,943.38 during the reporting period[3]. - Investment income for Q1 2023 significantly increased to RMB 56,075,010.44, compared to RMB 4,630,153.82 in Q1 2022[40]. - The company reported an investment income of ¥58,489,630.33 in Q1 2023, significantly up from ¥3,906,355.04 in Q1 2022[59]. Operational Efficiency - The company is focusing on optimizing its pharmaceutical business structure, which has led to a decrease in the scale of its pharmaceutical commercial operations[2]. - The company’s cash inflow from sales of goods and services was 744,733,760.68 RMB in Q1 2023, compared to 717,978,704.55 RMB in Q1 2022, showing a 3.7% increase[34]. - The company’s cash outflow for purchasing goods and services was 413,063,089.67 RMB in Q1 2023, down from 441,711,036.99 RMB in Q1 2022, representing a 6.5% decrease[34].